Recent developments in the field of antitumour anthracyclines.
Monneret
C
C
Laboratoire de Pharmacochimie, Unité mixte 176 CNRS/IC, Institut Curie, Section de Recherche, 26 rue d'Ulm, 75248 Cedex 05, Paris, France. claude.monneret@curie.fr
D015250:Aclarubicin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D000595:Amino Acid Sequence; D000818:Animals; D018943:Anthracyclines / Q000009:adverse effects / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D002360:Carubicin / Q000031:analogs & derivatives / Q000494:pharmacology; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D004317:Doxorubicin / Q000009:adverse effects / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D019008:Drug Resistance, Neoplasm; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*
D018943:Anthracyclines; D000970:Antineoplastic Agents; D015250:Aclarubicin; D004317:Doxorubicin; D002360:Carubicin; D003630:Daunorubicin